Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

T cells play a critical role in the control of cancer. The development of immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed in only a subset of patients, prompting research efforts to focu...

Descripción completa

Detalles Bibliográficos
Autores principales: Piovesan, Dana, Tan, Joanne B.L., Becker, Annette, Banuelos, Jesus, Narasappa, Nell, DiRenzo, Daniel, Zhang, Kristen, Chen, Ada, Ginn, Elaine, Udyavar, Akshata R., Yin, Fangfang, Paprcka, Susan L., Purandare, Bhamini, Park, Timothy W., Kimura, Nikki, Kalisiak, Jaroslaw, Young, Stephen W., Powers, Jay P., Schindler, Uli, Sivick, Kelsey E., Walters, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381133/
https://www.ncbi.nlm.nih.gov/pubmed/35405741
http://dx.doi.org/10.1158/1535-7163.MCT-21-0802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381133/
https://www.ncbi.nlm.nih.gov/pubmed/35405741
http://dx.doi.org/10.1158/1535-7163.MCT-21-0802

Ejemplares similares